BioWorld

Dec. 12, 2008

Pain Therapeutics, King Tumble On FDA's Remoxy Rejection

Shares of Pain Therapeutics Inc. plunged 21 percent Thursday after the San Mateo, Calif.-based firm said it received a complete response letter from the FDA for Remoxy, a controlled-release formulation of oxycodone. (BioWorld Today) Read More

Acusphere Hits Rock Bottom on Negative Panel Vote on Imagify

Infinity Takes Back HSP90 in Terminated AstraZeneca Deal

Vivus Hits Endpoints in First Qnexa Phase III Obesity Trial

Salix Bowel Cleansing Products Get FDA Black-Box Warning

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...